Aliases & Classifications for Cervix Carcinoma

MalaCards integrated aliases for Cervix Carcinoma:

Name: Cervix Carcinoma 12 14 69
Carcinoma of Cervix 12 28
Carcinoma of the Cervix Uteri 12
Carcinoma Cervix Uteri 12
Cancer of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2893
NCIt 46 C9039
UMLS 69 C0302592

Summaries for Cervix Carcinoma

Disease Ontology : 12 A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Cervix Carcinoma, also known as carcinoma of cervix, is related to high-grade neuroendocrine carcinoma of the cervix uteri and glassy cell carcinoma of the cervix uteri. An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are DNA Damage and MAPK Signaling: Mitogen Stimulation Pathway. The drugs Cisplatin and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include the cervix uteri or, cervix and testes, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 high-grade neuroendocrine carcinoma of the cervix uteri 12.3
2 glassy cell carcinoma of the cervix uteri 12.2
3 adenoid basal carcinoma of the cervix uteri 12.2
4 papillary carcinoma of the cervix uteri 12.2
5 cervix small cell carcinoma 11.5
6 cervical cancer 11.2
7 cervix uteri carcinoma in situ 11.1
8 cervical squamous cell carcinoma 11.0
9 cervical adenocarcinoma 11.0
10 primitive neuroectodermal tumor of the cervix uteri 11.0
11 suppressor of tumorigenicity 3 10.9
12 microsporidiosis 10.4 ABCB1 ABCC1
13 colchicine resistance 10.3 ABCB1 ABCC1
14 bone squamous cell carcinoma 10.3 STAT3 TP53
15 ophthalmia neonatorum 10.2 MAPK8IP1 STYK1
16 sarcomatoid squamous cell skin carcinoma 10.2 MAPK8IP1 TP53
17 megaesophagus 10.2 FHIT TP53
18 fallopian tube adenocarcinoma 10.2 MAPK8IP1 TP53
19 cervical carcinosarcoma 10.2 MAPK8IP1 TP53
20 aging 10.1 FOXO3 STAT3 TP53
21 lung cancer susceptibility 3 10.1 ABCC1 FOXM1 STAT3 TP53
22 reproductive organ cancer 10.1 MAPK8IP1 STAT3 TP53
23 acute lymphocytic leukemia 10.0 ABCB1 NBN TP53
24 non-invasive bladder papillary urothelial neoplasm 10.0 FGFR3 TP53
25 bladder papillary transitional cell neoplasm 10.0 FGFR3 TP53
26 urinary tract papillary transitional cell benign neoplasm 10.0 FGFR3 TP53
27 bladder urothelial carcinoma 9.9 FGFR3 FHIT TP53
28 pleomorphic adenoma carcinoma 9.9 BECN1 TP53
29 myeloma, multiple 9.7 ABCB1 FGFR3 STAT3 TP53
30 brain glioma 9.6
31 vulva cancer 9.6
32 urinary tract obstruction 9.6
33 glioma 9.6
34 blood group, i system 9.6
35 burkitt lymphoma 9.6
36 thyroid carcinoma, familial medullary 9.6
37 pigmentary disorder, reticulate, with systemic manifestations, x-linked 9.6
38 meningioma, familial 9.6
39 lymphoma 9.6
40 cervicitis 9.6
41 thyroiditis 9.6
42 peritonitis 9.6
43 in situ carcinoma 9.6
44 hypoxia 9.6
45 breast cancer 8.7 ABCB1 ABCC1 BECN1 CDC27 FHIT NBN

Graphical network of the top 20 diseases related to Cervix Carcinoma:



Diseases related to Cervix Carcinoma

Symptoms & Phenotypes for Cervix Carcinoma

MGI Mouse Phenotypes related to Cervix Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 STAT3 TP53 SLC16A1 FHIT ABCB1 FOXM1
2 hematopoietic system MP:0005397 10.07 STAT3 TP53 NBN FHIT ABCB1 ABCC1
3 digestive/alimentary MP:0005381 10.03 SLC16A1 STAT3 TP53 FHIT ABCB1 FOXM1
4 endocrine/exocrine gland MP:0005379 10.01 STAT3 TP53 NBN ABCB1 FOXM1 BECN1
5 immune system MP:0005387 9.96 STAT3 TP53 NBN FHIT ABCB1 FOXM1
6 mortality/aging MP:0010768 9.93 SLC16A1 STAT3 TP53 FHIT ABCB1 FOXM1
7 neoplasm MP:0002006 9.56 STAT3 TP53 FHIT FOXM1 FOXO3 BECN1
8 reproductive system MP:0005389 9.23 STAT3 TP53 NBN FGFR3 ABCB1 BECN1

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 444)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
3
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
4
Meperidine Approved Phase 4 57-42-1 4058
5
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
6
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
7
Nicotine Approved Phase 4,Phase 1,Phase 2 54-11-5 89594 942
8
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
9
Iron Approved Phase 4 7439-89-6 23925
10
Bethanechol Approved Phase 4 674-38-4 2370
11
Peppermint Approved, Nutraceutical Phase 4
12
Vitamin C Approved, Nutraceutical Phase 4,Phase 2 50-81-7 54670067 5785
13 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
15 Epoetin alfa Phase 4,Phase 3 113427-24-0
16 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
17 Adjuvants, Anesthesia Phase 4,Phase 3
18 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
19 Analgesics, Opioid Phase 4,Phase 3
20 Anesthetics Phase 4,Phase 3,Phase 2,Early Phase 1
21 Anesthetics, General Phase 4,Phase 3
22 Anesthetics, Intravenous Phase 4,Phase 3
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Early Phase 1
24 Narcotics Phase 4,Phase 3,Early Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2
30 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
31 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
32 Fluorodeoxyglucose F18 Phase 4,Phase 3,Phase 2,Phase 1
33 Disinfectants Phase 4
34 Hypoglycemic Agents Phase 4,Phase 2
35 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
36 Polyhexamethylene biguanide Phase 4
37 Antidepressive Agents Phase 4,Phase 2
38 Antidepressive Agents, Second-Generation Phase 4,Phase 2
39 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
40 Dopamine Agents Phase 4,Phase 2
41 Dopamine Uptake Inhibitors Phase 4,Phase 2
42 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
43 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
44 Central Nervous System Stimulants Phase 4,Phase 2,Phase 1
45 Cholinergic Agents Phase 4,Phase 1,Phase 2
46 Nicotinic Agonists Phase 4,Phase 1,Phase 2
47 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2
48 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2
49 Vitamins Phase 4,Phase 3,Phase 1,Phase 2
50 Ferrous fumarate Phase 4

Interventional clinical trials:

(show top 50) (show all 1204)

# Name Status NCT ID Phase Drugs
1 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
4 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
5 Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer Completed NCT01988376 Phase 4
6 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
7 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
8 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
9 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
10 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
11 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
12 Alternate Dosing Schedules Study for HPV Vaccine (ADS) Completed NCT02280642 Phase 4
13 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
14 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
15 Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy Completed NCT02684942 Phase 4 Meperidine;Fentanyl
16 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
17 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
18 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
19 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
20 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
21 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
22 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Recruiting NCT02837926 Phase 4
23 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
24 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
25 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Recruiting NCT01953107 Phase 4
26 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
27 FASTER-Tlalpan Study Active, not recruiting NCT03105856 Phase 4
28 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4 Tachosil
29 Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
30 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Active, not recruiting NCT01031069 Phase 4
31 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
32 To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer Not yet recruiting NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
33 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Not yet recruiting NCT02910596 Phase 4 bethanechol chloride
34 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Not yet recruiting NCT03423082 Phase 4 18F fluciclovine
35 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
36 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
37 Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs & Above Terminated NCT00730847 Phase 4
38 Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis Unknown status NCT00846508 Phase 3 Cisplatin
39 Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
40 Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
41 Usefulness of FDG-PET for Advanced Cervical Cancer Unknown status NCT00146458 Phase 3
42 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Unknown status NCT01554397 Phase 2, Phase 3 Cisplatin
43 Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome Unknown status NCT00348738 Phase 3 Erythropoietin
44 Hydralazine Valproate for Cervical Cancer Unknown status NCT00532818 Phase 3 Hydralazine and magnesium valproate;Placebo
45 Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma Unknown status NCT01405235 Phase 3 Paclitaxel;Cisplatin/Paclitaxel
46 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
47 Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients Unknown status NCT00122746 Phase 3
48 Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet. Unknown status NCT01414517 Phase 3
49 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
50 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3

Search NIH Clinical Center for Cervix Carcinoma

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

# Genetic test Affiliating Genes
1 Carcinoma of Cervix 28 FGFR3

Anatomical Context for Cervix Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Carcinoma:

18
The Cervix Uteri Or

MalaCards organs/tissues related to Cervix Carcinoma:

38
Cervix, Testes, Lymph Node, Breast, Lung, T Cells, Colon

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show all 49)
# Title Authors Year
1
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma. ( 28359677 )
2017
2
Extra-peritoneal laparoscopic para-aortic lymphadenectomy for staging of uterine cervix carcinoma. ( 28153518 )
2017
3
The induction of oxidative stress in cervix carcinoma cells by levoglucosenone derived 4-S-salicyl derivative and (1-4)-S-thio-disaccharides. Part 4. ( 28185719 )
2017
4
Dosimetric influence of filtered and flattening filter free photon beam on rapid arc (RA) radiotherapy planning in case of cervix carcinoma. ( 27790073 )
2017
5
DCE-MRI of patient-derived xenograft models of uterine cervix carcinoma: associations with parameters of the tumor microenvironment. ( 29100521 )
2017
6
Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. ( 27368915 )
2016
7
SU-F-T-62: Three-Dimensional Dosimetric Gamma Analysis for Impacts of Tissue Inhomogeneity Using Monte Carlo Simulation in Intracavitary Brachytheray for Cervix Carcinoma. ( 28048200 )
2016
8
STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. ( 26563366 )
2016
9
Image-Guided High-Dose Rate Brachytherapy in Cervix Carcinoma Using Balloon Catheter and Belt Immobilization System. ( 26868850 )
2016
10
Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique. ( 27504132 )
2016
11
Modulation of RhoA GTPase Activity Sensitizes Human Cervix Carcinoma Cells to I^-Radiation by Attenuating DNA Repair Pathways. ( 26649141 )
2016
12
RGDS- and TAT-Conjugated Upconversion of NaYF4:Yb(3+)/Er(3+)&SiO2 Nanoparticles: In Vitro Human Epithelioid Cervix Carcinoma Cellular Uptake, Imaging, and Targeting. ( 27428386 )
2016
13
Systematic gene microarray analysis of the lncRNA expression profiles in human uterine cervix carcinoma. ( 26054679 )
2015
14
Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience. ( 26034391 )
2015
15
Metastatic lobular carcinoma of breast mimics primary cervix carcinoma: two case reports and a review of the literature. ( 26435744 )
2015
16
The dosimetric impact of different photon beam energy on RapidArc radiotherapy planning for cervix carcinoma. ( 26865756 )
2015
17
Synthetic racemates of abyssinone I and II induces apoptosis through mitochondrial pathway in human cervix carcinoma cells. ( 25019692 )
2014
18
Cervix carcinoma and incidental finding of medullary thyroid carcinoma by 18F-FDG PET/CT--clinical case. ( 25088110 )
2014
19
A ROS-mediated lysosomal-mitochondrial pathway is induced by a novel Amonafide analogue, 7c, in human Hela cervix carcinoma cells. ( 23376642 )
2013
20
Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways. ( 24167031 )
2013
21
Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. ( 24074927 )
2013
22
Ultrasound-assisted endocavitary HDR-Ir(192) brachytherapy for unresectable locally advanced uterine cervix carcinoma: retrospective analysis focusing the efficacy and tolerability. ( 22855184 )
2013
23
Cervix carcinoma or Burkitt lymphoma metastases in meningiomas, two case reports. ( 23318021 )
2013
24
Bladder-rectum spacer balloon in high-dose-rate brachytherapy in cervix carcinoma. ( 23517809 )
2013
25
Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution. ( 23880416 )
2013
26
Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. ( 22633469 )
2012
27
Concomitant boost plus large-field preoperative chemoradiation in locally advanced uterine cervix carcinoma: Phase II clinical trial final results (LARA-CC-1). ( 22425663 )
2012
28
Uterine cervix carcinoma: recent biological data and update for improving follow-up and treatment. ( 23240379 )
2012
29
Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT. ( 22996235 )
2012
30
Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions. ( 21556123 )
2011
31
Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms. ( 20037485 )
2010
32
Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. ( 18484413 )
2008
33
Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. ( 18846503 )
2008
34
Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. ( 18217980 )
2008
35
Effect of NBS1 gene polymorphism on the risk of cervix carcinoma in a northern Indian population. ( 18949738 )
2008
36
Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. ( 18505570 )
2008
37
CDC27 protein is involved in radiation response in squamous cell cervix carcinoma. ( 23923534 )
2005
38
Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. ( 16004614 )
2005
39
Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcinomas. ( 15138927 )
2004
40
Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. ( 12586590 )
2003
41
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. ( 12438219 )
2002
42
Stage IIa cervix carcinoma with metastasis to the heart: report of a case with immunohistochemistry, flow cytometry, and virology findings. ( 10620458 )
2000
43
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. ( 10471491 )
1999
44
Expression of transglutaminase K in normal cervix tissue and cervix carcinomas. ( 10405818 )
1999
45
Response to radiotherapy of human uterine cervix carcinoma is not correlated with rearrangements of the Ha-ras-1 and/or c-myc genes. ( 9291819 )
1997
46
Cathepsin B in predicting the extent of the cervix carcinoma. ( 7617069 )
1995
47
[CD44 splice variants as prognostic factors in invasive cervix carcinoma]. ( 7537136 )
1995
48
c-erbB-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. ( 8526205 )
1995
49
Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas. ( 1683873 )
1991

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Pathways for Cervix Carcinoma

GO Terms for Cervix Carcinoma

Cellular components related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.17 BECN1 FHIT FOXO3 MAPK8IP1 SLC16A1 STAT3

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.85 BECN1 CDKN3 FOXM1 NBN TP53
2 glucose homeostasis GO:0042593 9.58 FOXO3 SLC16A1 STAT3
3 peptidyl-tyrosine dephosphorylation GO:0035335 9.54 CDKN3 DUPD1 DUSP3
4 aging GO:0007568 9.46 BECN1 FOXO3 STAT3 TP53
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 FOXM1 TP53
6 regulation of mitochondrial membrane permeability GO:0046902 9.32 STAT3 TP53
7 xenobiotic transport GO:0042908 9.26 ABCB1 ABCC1
8 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.13 FOXO3 NBN TP53
9 response to drug GO:0042493 9.1 ABCB1 ABCC1 BECN1 FOXO3 STAT3 TP53

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatase activity GO:0016791 9.58 CDKN3 DUPD1 DUSP3
2 protein tyrosine phosphatase activity GO:0004725 9.54 CDKN3 DUPD1 DUSP3
3 protein phosphatase binding GO:0019903 9.5 CDC27 STAT3 TP53
4 transcription cofactor binding GO:0001221 9.26 FOXO3 TP53
5 protein kinase binding GO:0019901 9.17 BECN1 DUSP3 FOXM1 FOXO3 MAPK8IP1 STAT3
6 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.16 ABCB1 ABCC1
7 protein tyrosine/serine/threonine phosphatase activity GO:0008138 9.13 CDKN3 DUPD1 DUSP3

Sources for Cervix Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....